Tus kws tshuaj ntsuam zaum ntawm laj kab thaum pib Calliditas Hais txog 'Lub Sijhawm Ze Rau Lub Sijhawm Tab sis Cov Lus Nug Ntev'

• Guggenheim pib kev pab them nqi rau Calliditas Therapeutics AB (Nasdaq: CALT) nrog qhov ntsuas nruab nrab thiab ib qho $18 tus nqi phiaj.

• Tus kws tshuaj ntsuam tau zoo siab rau cov ntaub ntawv Tarpeyo tau tsim hauv Immunoglobulin A Nephropathy (IgAN) rau hnub tim thiab thawj qhov kev vam meej uas lub tuam txhab tau muaj nrog kev lag luam tawm ntawm cov khoom.

• Thaum tus kws tshuaj xyuas qhuas pab pawg Calliditas rau lawv qhov kev nce qib nrog Tarpeyo hauv IgAN, suav nrog tau txais FDA Accelerated Approval thiab EU Conditional Approval, nws sau tseg cov kws kho mob cov lus pom zoo, nrog qee qhov pom zoo Tarpeyo ncua sij hawm tso tawm mechanism muab nqi dua ib txwm muaj steroid tab sis lwm tus xav tias qhov ntawd tus nqi yog tsim nyog tus nqi ntxiv.

• Cov kws kho mob tshwm sim "ntau dua los siv" endothelin receptor antagonists (ERAs) lossis ntau txoj hauv kev tshiab dhau sijhawm, ntxiv rau tus kws tshuaj ntsuam.

• FY22 Tarpeyo muag tau txog $ 36.8 lab. Tus kws tshuaj ntsuam xav tau txuas ntxiv mus nrog kev tshaj tawm thiab kwv yees qhov siab tshaj 2028 US Tarpeyo muag ntawm ~ $ 350 lab ua ntej poob kev suav nrog hauv 2029.

• Nqe Nqis: CALT shares tau nce 2.90% ntawm $ 19.50 ntawm daim tshev kawg hnub Wednesday.

Qhov Ntsuas Tseeb rau CALT

Saib Ntau Cov Kev Ntsuas Ntsuas rau CALT

Saib Qhov Ntsuam Kev Ntsuam Xyuas Cov Ntaus Tawm Tshiab

Tsis txhob nco lub sijhawm ceeb toom ntawm koj cov khoom lag luam - koom Lub Npe Lub Npe Pro dawb! Sim cov cuab yeej uas yuav pab koj nqis peev smarter, sai dua, thiab zoo dua.

Tshooj no Tus kws tshuaj ntsuam zaum ntawm laj kab thaum pib Calliditas Hais txog 'Lub Sijhawm Ze Rau Lub Sijhawm Tab sis Cov Lus Nug Ntev' Ameslikas nyob rau hauv benzinga.com

.

© 2023 Benzinga.com. Benzinga tsis muab lus qhia txog peev. Qoob loo.